ALK and anaplastic large cell lymphoma: One real-world study of lymphoma in a Swedish population showed that PTCL patients (excluding those with ALK+ALCL) receiving ASCT had better progression-free survival (HR: 0.56 [0.39-0.80]) and overall survival (OS; HR: 0.58 [0.40-0.84]), but the control group may enroll patients who did not respond to the initial chemotherapy (17).